Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
India
· Delayed Price · Currency is INR | Market Cap | 32.25B |
| Revenue (ttm) | 6.28B |
| Net Income (ttm) | 1.33B |
| Shares Out | 111.88M |
| EPS (ttm) | 11.87 |
| PE Ratio | 24.28 |
| Forward PE | n/a |
| Dividend | 5.10 (1.76%) |
| Ex-Dividend Date | n/a |
| Volume | 70,100 |
| Average Volume | 137,669 |
| Open | 286.00 |
| Previous Close | 288.25 |
| Day's Range | 285.35 - 293.00 |
| 52-Week Range | 257.90 - 571.00 |
| Beta | 0.42 |
| RSI | 49.93 |
| Earnings Date | May 9, 2025 |
About NSE:ADVENZYMES
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and animal nutrition, fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specia... [Read more]
Financial Performance
In 2023, NSE:ADVENZYMES's revenue was 6.24 billion, an increase of 15.39% compared to the previous year's 5.41 billion. Earnings were 1.33 billion, an increase of 26.19%.
Financial StatementsNews
Advanced Enzymes shares fall 8% after weak Q2 FY25 results
Advanced Enzyme Technologies shares dropped over 8% in morning trading following disappointing Q2 FY25 results. The company reported a 7.4% year-over-year revenue drop to ₹146.1 crore, down from ₹157....
Advanced Enzyme Technologies Q2 FY25: Revenue declines 7.4% YoY to ₹146.1 crore, Net Profit falls 5.1% YoY
Advanced Enzyme Technologies recently released its financial results for the second quarter of FY25, showing a decrease in both revenue and net profit compared to the same period last year. The compan...